Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients
NCT ID: NCT01717105
Last Updated: 2012-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
225 participants
OBSERVATIONAL
2011-03-31
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
metastatic non-small cell lung cancer
Only epidermal growth factor receptor (EGFR) M+ patients will be eligible for the study assessments
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) (patients stage III B unsuitable for locoregional treatment, and stage IV).
* Chemo- naïve patients (Non-Small-Cell Lung Cancer patients who have not received first line systemic cytotoxic chemotherapy).
* Patients with available tumoral tissue (primary tumor or metastatic area) or cytological samples including fine needle aspirates (primary tumor or metastatic area), bronchial alveolar lavage or bronchial scrapings and pleural effusion.
* Patients who have granted their written informed consent.
* Patients with documented positive mutation in epidermal growth factor receptor (EGFR) (M+).
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Dynamic Solutions
INDUSTRY
Grupo Gallego de Cancer de Pulmon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sergio Vázquez Estévez, Doctor
Role: STUDY_DIRECTOR
Grupo Gallego de Cáncer de Pulmón (GGCP)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centro Oncologico de Galicia
A Coruña, A Coruña, Spain
Complexo Hospitalario Arquitecto Marcide
Ferrol, A Coruña, Spain
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, A Coruña, Spain
Lucus Augusti Hospital
Lugo, Lugo, Spain
Complejo Hospitalario de Ourense
Ourense, Orense, Spain
Complexo Hospitalario de Pontevedra
Pontevedra, Pontevedra, Spain
Hospital do Meixoeiro
Vigo, Pontevedra, Spain
Hospital Xeral-Cíes
Vigo, Pontevedra, Spain
Hospital Povisa
Vigo, Pontevedra, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GGC-CPN-2010-01
Identifier Type: OTHER
Identifier Source: secondary_id
GGCP 048-10
Identifier Type: -
Identifier Source: org_study_id